Our findings link the interaction between dyslipidemia and cancer metastasis and provide new insight into coincident ANGPTL4 and NOX4 expression as a potential diagnostic biomarker and therapeutic target for CRC therapy. Here, ANGPTL4 is linked to metabolic syndrome.